Prof. Umberto Vespasiani Gentilucci

Associate Professor of Internal Medicine and Deputy Director of the School of Specialization in Internal Medicine at theUniversità Campus Bio-Medico di Roma, from a healthcare point of view, he is responsible for highly specialized professional functions (complex functions) in the Internal Medicine and Hepatology Area of ​​the Fondazione Universitario Policlinico Campus Bio-Medico of Rome. The research activity, in collaboration with national and international groups, is mainly focused on metabolic and autoimmune liver diseases, with particular reference to genetic predisposition factors and non-invasive stratification of the risk of disease progression. He is the author or co-author of more than 130 original articles published in international journals with impact factor.

He obtained his high school diploma in classical studies in 1996, and in 2002 he graduated in Medicine and Surgery at theUniversità Campus Bio-Medico di Roma with a grade of 110/110 and honors and in 2007 he specialized in Internal Medicine at the same University with a grade of 50/50 and honors. In 2012 he became a Doctor of Research in Hepatology at the University La Sapienza of Rome, in 2013 he obtained the second level Master's degree in Entrepreneurship in Healthcare at theUniversità Campus Bio-Medico di Roma and in 2016 he obtained the Master's Degree in Dietetics and Nutrition at the Catholic University of the Sacred Heart. In April 2016 he became a university researcher in Internal Medicine and in November 2019 Associate Professor of Internal Medicine at theUniversità Campus Bio-Medico di Roma.

From a professional point of view, after 2 years of consultancy activity (2007-2009), in 2010 he became responsible for simple professional functions, and from November 2019 for highly specialized professional functions (complex functions), at the Internal Medicine and Hepatology Area of ​​the Policlinico Campus Bio-Medico in Rome. Between 2013 and 2017 he also carried out scientific consultancy activities for the Italian Medicines Agency (AIFA) and the European Medicine Agency (EMA).

From a teaching point of view, since the academic year 2013/2014 he has been a teacher for the Internal Medicine and Geriatrics course, since the academic year 2016-2017 for the Semiotics course, in the Degree course in Medicine, and since the academic year 2020 in the Doctorate of Integrated Biomedical Sciences and Bioethics and Surgery of theUniversità Campus Bio-Medico di RomaSince November 2022 he has been Vice-Director of the School of Specialization in Medicine of theUniversità Campus Bio-Medico di Roma.

He is author or co-author of more than 130 original articles published in international journals with impact factor, and has participated as a collaborator in more than 30 other works always published in international journals with impact factor. He is in the Editorial Board (Associate Editor, Academic Editor, Editorial Board Member) of international scientific journals. He has received national and international funding for research projects.

14 selected publications in the last 5 years:

1) Vespasiani-Gentilucci U, De Vincentis A, Ferrucci L, et al. Low Alanine Aminotransferase Levels in the Elderly: Frailty, Disability, Sarcopenia and Reduced Survival. J Gerontol A Biol Sci Med Sci 2018.

2) Vespasiani-Gentilucci U, Gallo P, Dell'Unto C, Volpentesta M, Antonelli-Incalzi R, Picardi A. Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. World J Gastroenterol 2018.

3) De Vincentis A, Mancina RM, Pihlajamäki J, … and Vespasiani-Gentilucci U. Genetic variants in the MTHFR are not associated with fatty liver disease. Liver Int 2020.

4) Carotti S, Aquilano K, Zalfa F, Ruggiero S, … and Vespasiani-Gentilucci U. Lipophagy Impairment Is Associated With Disease Progression in NAFLD. Front Physiol 2020.

5) Carotti S, Aquilano K, Valentini F,… and Vespasiani-Gentilucci U. An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase. Am J Physiol Gastrointest Liver Physiol 2020.

6) Tavaglione F, De Vincentis A, Jamialahmadi O, …and Vespasiani-Gentilucci U. Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. JHEP Rep. 2021.

7) De Vincentis A, Tavaglione F, Jamialahmadi O, … and Vespasiani-Gentilucci U. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clin Gastroenterol Hepatol 2021.

8) Gallo P, De Vincentis A, Bandinelli S, Ferrucci L, … and Vespasiani-Gentilucci U. Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients. Aging Clin Exp Res 2021.

9) Carotti S., Lettieri-Barbato D., Piemonte F., … and Vespasiani Gentilucci U. Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver. Cell Death & Disease 2021.

10) De Vincentis A., Tavaglione F., Spagnuolo R., … and Vespasiani Gentilucci U. Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. INTERNATIONAL JOURNAL OF OBESITY 2021.

11) Tavaglione F., De Vincentis A., Bruni V., … Vespasiani Gentilucci U. and Romeo S. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. LIVER INTERNATIONAL 2022.

12) De Vincentis A., Tavaglione F., Jamialahmadi O., … and Vespasiani Gentilucci U. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2022.

13) Tavaglione F, De Vincentis A, Bruni V, … Vespasiani-Gentilucci U and Romeo S. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Liver Int 2022.

14) Tavaglione F, Jamialahmadi O, De Vincentis A, … Vespasiani-Gentilucci U and Romeo S. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2022.